Dutch Court Case On Humira Assesses Whether Its Price Was `Excessive’

Written by

in

Packaging for AbbVie’s drug, Humira (adalimumab). The Pharmaceutical Accountability Foundation in … More the Netherlands alleges in court that AbbVie made “excessive profits” during the period from 2014 to 2018, prior to its going off patent in Europe. AbbVie denies the allegations. (AP Photo/David J. Phillip, File)

Copyright 2016 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistribu

In a unique legal challenge, the Dutch…

Continue Reading

News Source: www.forbes.com

Comments

Leave a Reply Cancel reply

More posts